NEW DELHI (PTI): The Drugs Controller General of India has approved an anti-COVID oral drug, developed by DRDO, for emergency use as adjunct therapy in moderate to severe coronavirus patients, the defence ministry has said.
It said clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories in Hyderabad.
The 2-DG comes in powder form in sachet and is taken orally by dissolving it in water.
"On May 01, DCGI granted permission for emergency use of this drug as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country," the ministry said in a statement last on Saturday.
"It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally-infected cells makes this drug unique," the ministry said.
DCGI approves anti-COVID drug developed by DRDO for emergency use
Article Posted on : - May 10, 2021
Other Related News
HAL delivers first AL-31FP aero engine of Su30MKI to IAF under new contract
Hindustan Aeronautics Limited has handed over the first AL-31FP Aero Engine, manufactured under the 240 engine contract, to the Indian Air Force at Koraput in Odisha.
The Indian Air Force, in its flight trials evaluation report submitted before the Defence Ministry l..
view articleAn insight into the Medium Multi-Role Combat Aircraft competition...
view articleSky enthusiasts can now spot the International Space Station (ISS) commanded by Indian-American astr..
view article